Bristol Myers Squibb’s Zeposia Fails to Meet Primary Endpoint in Crohn’s Disease Trial
Bristol Myers Squibb (BMS; NYSE: BMY) has announced that a Phase III study for its...
Regenxbio Reports Stable Visual Acuity Improvements with AbbVie’s Gene Therapy in Wet AMD Trial
Regenxbio (NASDAQ: RGNX), the development partner for AbbVie’s (NYSE: ABBV) gene therapy ABBV-RGX-314, has announced...
Gilead Strikes Deal with Xilio Therapeutics for Tumor-Activated IL-12 Candidate
Gilead Sciences (NASDAQ: GILD) has announced an in-licensing agreement with fellow US biotechnology company Xilio...
Alphamab Oncology Reports 31.12% Revenue Growth in 2023 with Continued R&D Focus
Alphamab Oncology (HKG: 9966), a Chinese biopharmaceutical company, has released its financial performance and business...
Bio-Thera Solutions Reports 54.86% YOY Revenue Growth in 2023, Led by Biosimilar Sales
Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company headquartered in Guangzhou, has announced its financial results...
Broncus Medical Inc. Reports 32% YOY Growth in 2023, Highlighted by Strength in China
Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung diseases with...
Jiangsu Hengrui’s SHR-A1921 Earns FDA Fast-Track Status for Platinum-Resistant Ovarian Cancer Therapies
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a distinguished pharmaceutical entity, has announced that it...
Hengrui Pharmaceuticals Advances Clinical Trial for PD-L1 Inhibitor Combo in CLDN18.2 Positive Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company, has received approval from...
Allergan Aesthetics Launches SKINMEDICA in China, Targeting Booming Skincare Market
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the market launch of its...
InnoCare Pharma Initiates Phase Ib Study Combining ICP-189 with Furmonertinib for NSCLC
InnoCare Pharma (HKG: 9969, SHA: 688428), a biopharmaceutical company , has announced that the first...
Novatim Immune Therapeutics’ KQ-2003 Gains Tacit Approval for POEMS Syndrome Clinical Trial in China
Novatim Immune Therapeutics (Zhejiang) Co., Ltd, a China-based specialist in cancer immunotherapy, has received tacit...
Harbour BioMed Reports Triple-Digit Revenue Growth and First-Ever Net Profit in 2023 Financial Results
Harbour BioMed (HKG: 2142), a biopharmaceutical company with a global presence in Suzhou, China, Cambridge...
Hepalink’s Enoxaparin Sodium Injection Receives Marketing Approval in New Zealand
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a prominent pharmaceutical company based in China,...
IASO Biotherapeutics Gets NMPA Go-Ahead for BCMA-Targeted CAR-T Therapy Clinical Trial
IASO Biotherapeutics, a China-based biopharmaceutical company, has announced that it has received approval from the...
WuXi AppTec Denies US Allegations of Unauthorized Intellectual Property Transfer
WuXi AppTec (SHA: 603259, HKG: 2359), a leading Contract Research, Development, and Manufacturing Organization (CRDMO)...
China’s National Joint Procurement Office Announces Renewal of Insulin Procurement Contracts Valued at $1.59 Billion
The National Joint Procurement Office in China has announced the renewal of drug procurement contracts...
FDA Reviews Eisai’s Leqembi for Expanded Use as Monthly Alzheimer’s Therapy
The US Food and Drug Administration (FDA) has given the green light to review an...
WuXi AppTec Denies Unauthorized IP Transfer Allegations Amidst Strong Financial Performance
WuXi AppTec (SHA: 603259, HKG: 2359), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO)...
Genor Biopharma’s Lerociclib Accepted for Review by China’s NMPA for Breast Cancer Treatment
China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced that the market filing for its...
BeiGene and GenFleet Join Forces for DLBCL Trial Combining Brukinsa and GFH009
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotechnology company, has entered into...